<DOC>
	<DOCNO>NCT02730403</DOCNO>
	<brief_summary>This observational , `` ancillary study '' intend describe opioid use among opioid use disorder patient follow discharge community inpatient detoxification and/or short-term residential treatment program affiliate parent study CTN-0051 , assess comparative effectiveness extend release injectable naltrexone ( XR-NTX , Vivitrol® ) , opioid antagonist recently approve indicated prevention relapse opioid dependence , versus buprenorphine-naloxone ( BUP-NX , Suboxone® ) , high affinity partial agonist indicate maintenance treatment opioid dependence , pharmacotherapeutic aid recovery .</brief_summary>
	<brief_title>TAU Opioid Use Outcomes Following Discharge From Detoxification Short Term Residential Programs Affiliated With CTN-0051</brief_title>
	<detailed_description>Participant recruitment begin recruitment CTN-0051 complete . Opioid use disorder patient recruit prior leave detoxification and/or short-term residential program . Screening baseline data ( focused demographic , diagnosis service utilization ) collect prior discharge , follow-up data ( focused opioid use ) collect week 1 , 4 8 follow discharge .</detailed_description>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<criteria>18 year old ; Meet DSM5 criterion opioiduse disorder ( heroin prescription opioids ) ; Have use opioids specifically prescribe within thirty day prior consent Seeking treatment opioid dependence ; Able provide write informed consent ; Able speak English sufficiently understand study procedure . Serious medical , psychiatric substance use disorder , opinion Site PI , would make participation hazardous participant , compromise study finding prevent participant completing study ; Suicidal homicidal ideation require immediate attention ; Maintenance methadone dose 30mg great time sign consent ; Presence pain sufficient severity require ongoing pain management opioids ; Pending legal action reason might prevent individual completing study ; If female , currently pregnant breastfeed planning conception ; Prior participation parent trial CTN0051</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>